TY  - JOUR
AU  - Roßner, Florian
AU  - Sinn, Bruno Valentin
AU  - Horst, David
TI  - Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update.
JO  - Cancers
VL  - 15
IS  - 2
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - DKFZ-2023-00146
SP  - 494
PY  - 2023
AB  - Combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer that is composed of both hepatocellular and cholangiocellular differentiated cells. It is slightly more common in men and among Asian and Pacific islanders. Overall, risk factors are similar to classic risk factors of hepatocellular carcinoma (HCC). The classification has significantly evolved over time. The last WHO classification (2019) mainly emphasized diagnosis on morphological basis with routine stainings, discarded previously recognized classifications with carcinomas with stem cell features, introduced intermediate cell carcinoma as a specific subtype and considered cholangiolocarcinoma as a subtype of cholangiocellular carcinoma. Immunohistochemical markers may be applied for further specification but have limited value for diagnosis. Recent discoveries in molecular pathway regulation may pioneer new therapeutic approaches for this poor prognostic and challenging diagnosis.
KW  - cHCC-CCA (Other)
KW  - cholangiocarcinoma (Other)
KW  - combined hepatocellular and cholangiocellular carcinoma (Other)
KW  - hepatocellular carcinoma (Other)
KW  - hippo signaling (Other)
KW  - mixed carcinoma (Other)
KW  - progenitor cells (Other)
KW  - stem cells (Other)
KW  - wnt signaling (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36672443
C2  - pmc:PMC9856551
DO  - DOI:10.3390/cancers15020494
UR  - https://inrepo02.dkfz.de/record/212427
ER  -